Johanna Friedl-Naderer Sells 900 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Johanna Friedl-Naderer sold 900 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $24.35, for a total value of $21,915.00. Following the completion of the sale, the insider owned 153,082 shares in the company, valued at approximately $3,727,546.70. This represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Johanna Friedl-Naderer also recently made the following trade(s):

• On Tuesday, September 8th, Johanna Friedl-Naderer sold 185 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.88, for a total value of $3,492.80.

Dyne Therapeutics Trading Down 5.5%

NASDAQ:DYN opened at $19.19 on Thursday. Dyne Therapeutics, Inc. has a 1 year low of $11.92 and a 1 year high of $27.31. The stock has a market cap of $3.58 billion, a price-to-earnings ratio of -5.76 and a beta of 1.08. The business has a fifty day moving average of $24.77 and a 200-day moving average of $20.52. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). Equities analysts predict that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current year.

Analysts Set New Price Targets

DYN has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from a “neutral” rating to an “underweight” rating and lowered their price objective for the company from $17.00 to $10.00 in a research note on Wednesday. Morgan Stanley decreased their price target on Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating for the company in a research note on Wednesday. Royal Bank Of Canada lowered their price target on Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday. Robert W. Baird dropped their price objective on Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, TD Cowen assumed coverage on Dyne Therapeutics in a report on Friday, June 26th. They set a “buy” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.17.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC acquired a new position in shares of Dyne Therapeutics in the 2nd quarter worth $300,000. Nykredit A S acquired a new stake in shares of Dyne Therapeutics during the second quarter worth $113,000. California State Teachers Retirement System lifted its holdings in shares of Dyne Therapeutics by 2,049.2% during the second quarter. California State Teachers Retirement System now owns 3,001,615 shares of the company’s stock valued at $66,666,000 after purchasing an additional 2,861,952 shares during the last quarter. Moore Capital Management LP lifted its holdings in shares of Dyne Therapeutics by 288.2% during the second quarter. Moore Capital Management LP now owns 305,794 shares of the company’s stock valued at $6,792,000 after purchasing an additional 227,029 shares during the last quarter. Finally, Two Sigma Securities LLC acquired a new position in shares of Dyne Therapeutics in the 2nd quarter valued at $222,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Key Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada maintained an “outperform” rating, although it reduced its price target from $35 to $30. RBC said Dyne’s DYNE-101, or z-basivarsen, has important differences from Novartis’ program that could support better outcomes. RBC analysis of Dyne’s DM1 approach
• Positive Sentiment: Dyne is scheduled to present six- and 12-month ACHIEVE trial data for z-basivarsen at the World Muscle Society and AANEM meetings beginning September 29-30. The company expects topline results from its fully enrolled registrational expansion cohort in the first quarter of 2027. Dyne ACHIEVE data announcement
• Neutral Sentiment: JPMorgan downgraded DYN from “neutral” to “underweight” and cut its price target from $17 to $10, while RBC remained bullish. The sharply conflicting views highlight significant uncertainty ahead of Dyne’s clinical updates. JPMorgan downgrade report
• Neutral Sentiment: Call-option activity increased dramatically, with traders purchasing more than 20,000 calls versus an average of roughly 464. This may indicate speculative expectations for a rebound or favorable clinical data, but it does not establish a fundamental improvement.
• Negative Sentiment: Investors appear to be treating the Novartis Phase 3 failure as a warning for the DM1 drug class, causing a sharp decline in Dyne shares despite the company’s upcoming data. Report on rival DM1 trial failure
• Negative Sentiment: Several insiders, including CEO John Cox, reported stock sales. The filings state that the sales were made to cover tax withholding on vested equity awards, reducing their negative significance, but the cluster may add to cautious sentiment.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.